Q-omics provides the consensus-scored TADA3 profile across patient tissues and cancer cell-line models. TADA3 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TADA3 is differentially expressed in 11, with the highest sampling consensus in LIHC. Additionally, TADA3 protein abundance shows 21,045 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, LIHC, and GBM as cancer lineages where TADA3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TADA3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TADA3 survival associations across molecular data types. TADA3 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TADA3 RNA expression–survival associations across cancer types. High TADA3 expression shows unfavorable associations in ACC, KICH, LAML and LIHC, but favorable associations in UVM and SKCM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for TADA3 RNA expression.
This table summarizes TADA3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in LIHC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for TADA3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TADA3 shows higher tumor expression in LIHC, CHOL, KIRP, STAD, HNSC and BRCA. The LIHC box plot shows higher TADA3 RNA expression in tumor versus normal tissue (log2 FC = +0.918, t-test p < 0.001).
This table shows molecular features associated with TADA3 in patient tissues and cancer cell lines. In patient samples, TADA3 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, TADA3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Leukemia.
